Credit Agricole Entreprises

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

3DRudder, established in 2014 and based in Marseille, France, specializes in designing and manufacturing feet-powered controllers for virtual reality (VR) and 3D environments. Their flagship product, a foot-powered motion controller, enables users to navigate and interact within VR and 3D spaces while seated, using natural foot movements for a more immersive experience. The company caters to gaming, 3D design, and machine control markets, and also offers research and development services for computer game hardware and 3D technologies.

Hikob is a company focused on creating wireless autonomous data acquisition systems that capture complex information from physical assets and environments. Its technology is designed to operate in diverse and challenging contexts, including outdoor settings and harsh conditions, making it suitable for a wide range of applications. The systems are fully integrated hardware and software platforms that enable users to collect and analyze data efficiently, supporting advanced data processing algorithms. By facilitating the collection of real-time data directly from assets, Hikob's solutions help businesses enhance their understanding, improve operational efficiency, and reduce costs associated with traditional wired systems. The company plays a vital role in enabling organizations to leverage IoT technologies, allowing for innovative product development and customized monitoring projects to optimize the management of industrial assets.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Cortus is an ASIC and system-on-chip design company that specializes in providing tailored intelligent processing solutions. As a founding platinum member of the RISC-V Foundation, Cortus offers a diverse range of in-house intellectual properties, including both proprietary and RISC-V instruction set architecture processors, analog circuits, interconnect IP, coherent caches, and system-level components. The company also develops comprehensive software solutions, such as compilers, real-time operating systems, and embedded software, enabling seamless integration of hardware and software for its clients. Cortus has created complete system-on-chip solutions for various applications, including a notable IoT platform that features a medium-range RF transceiver, a powerful microcontroller, and hardware-based AES encryption, all designed for energy efficiency and extended battery life. With over 6 billion devices utilizing its IPs, Cortus delivers significant competitive advantages across multiple sectors, including automotive, banking, and space applications.

Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA. Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).